Belgium
Anabiotec, founded in 1999 and headquartered in Belgium, positions itself as a pivotal player in the Analytics and Biotechnology industries. The company serves as an "independent partner for CMC analytics and (pre-)clinical bioanalysis," offering comprehensive analytical drug development solutions tailored to the pharmaceutical and biotech sector.
With a broad service range encompassing Small Molecules, Biologics, and Cell & Gene Therapy products, Anabiotec addresses various phases of drug development, including preclinical, clinical, and commercial stages. This strategy leverages over 25 years of expertise in analytical method development and validation, facilitating risk mitigation and accelerating project timelines.
Their seasoned scientific project managers play a crucial role in project continuity and milestone achievement, enhancing their value proposition. Despite their longstanding presence, the absence of a disclosed recent investment may indicate a stable financial footing or a potential opportunity for capital infusion to expand services or breadth.
